JO2887B1 - Spiro-pyridine compounds as ORL-1 receptor antagonists - Google Patents

Spiro-pyridine compounds as ORL-1 receptor antagonists

Info

Publication number
JO2887B1
JO2887B1 JO2010386A JOP20100386A JO2887B1 JO 2887 B1 JO2887 B1 JO 2887B1 JO 2010386 A JO2010386 A JO 2010386A JO P20100386 A JOP20100386 A JO P20100386A JO 2887 B1 JO2887 B1 JO 2887B1
Authority
JO
Jordan
Prior art keywords
orl
receptor antagonists
spiropiperidine compounds
spiropiperidine
compounds
Prior art date
Application number
JO2010386A
Other languages
Arabic (ar)
English (en)
Inventor
بيلين بونيتو كولادو انا
دياز بوزو نوريا
بيدريجال تيرسيرو كونسيبسيون
ماريا جيمينيز-اجوادو الما
لافونت بلانكو سيليا
انجليز مارتينيز -جرو ماريا
انجل توليدو اسكريبانو ميجويل
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2887B1 publication Critical patent/JO2887B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JO2010386A 2009-11-16 2010-11-03 Spiro-pyridine compounds as ORL-1 receptor antagonists JO2887B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
JO2887B1 true JO2887B1 (en) 2015-03-15

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2010386A JO2887B1 (en) 2009-11-16 2010-11-03 Spiro-pyridine compounds as ORL-1 receptor antagonists

Country Status (34)

Country Link
US (1) US8232289B2 (enExample)
EP (1) EP2501703B1 (enExample)
JP (1) JP5680101B2 (enExample)
KR (1) KR101363830B1 (enExample)
CN (1) CN102612520B (enExample)
AR (1) AR078863A1 (enExample)
AU (1) AU2010319581C1 (enExample)
CA (1) CA2796161C (enExample)
CO (1) CO6541545A2 (enExample)
CR (1) CR20130087A (enExample)
DK (1) DK2501703T3 (enExample)
DO (1) DOP2012000135A (enExample)
EA (1) EA020848B1 (enExample)
EC (1) ECSP12011902A (enExample)
ES (1) ES2435814T3 (enExample)
HN (1) HN2012001011A (enExample)
HR (1) HRP20130967T1 (enExample)
IL (1) IL219370A (enExample)
JO (1) JO2887B1 (enExample)
MA (1) MA33751B1 (enExample)
ME (1) ME01537B (enExample)
MX (1) MX2012005691A (enExample)
MY (1) MY160665A (enExample)
NZ (1) NZ600006A (enExample)
PE (1) PE20121430A1 (enExample)
PH (1) PH12012500969A1 (enExample)
PL (1) PL2501703T3 (enExample)
PT (1) PT2501703E (enExample)
RS (1) RS53018B (enExample)
SI (1) SI2501703T1 (enExample)
TW (1) TWI465453B (enExample)
UA (1) UA107943C2 (enExample)
WO (1) WO2011060035A1 (enExample)
ZA (1) ZA201202967B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201401661RA (en) 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
NZ739834A (en) 2012-10-02 2018-11-30 Bayer Cropscience Ag Heterocyclic compounds as pesticides
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
JP7146782B2 (ja) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
LT3589638T (lt) 2017-03-02 2021-06-10 Eli Lilly And Company Junginiai, naudingi ror-gama-t slopinimui
JP6766274B2 (ja) * 2017-03-02 2020-10-07 イーライ リリー アンド カンパニー Ror−ガンマ−tを阻害するのに有用な化合物
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
KR102746817B1 (ko) 2018-02-16 2024-12-24 스미토모 파마 아메리카, 인크. 염, 결정 형태 및 이들의 제조 방법
CA3121910A1 (en) 2018-12-17 2020-06-25 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
AU2021257786A1 (en) 2020-04-14 2022-11-03 Sunovion Pharmaceuticals Inc. (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine for treating neurological and psychiatric disorders
IL318169A (en) 2020-08-26 2025-03-01 Vertex Pharma Apol1 inhibitors and methods of use are the same
AU2023218994A1 (en) * 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス.エイ. ノシセプチン受容体親和性を有するトリアゾスピロ化合物
NZ528978A (en) * 2001-04-18 2004-06-25 Euro Celtique S Spiropyrazole compounds
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
ATE396995T1 (de) * 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Orl−1受容体リガンドとしてのn置換スピロピペリジン化合物
JPWO2003095427A1 (ja) 2002-05-10 2005-09-15 大正製薬株式会社 スピロ環化合物
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
KR20050043935A (ko) * 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Orl-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
CL2009000731A1 (es) * 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.

Also Published As

Publication number Publication date
WO2011060035A1 (en) 2011-05-19
JP5680101B2 (ja) 2015-03-04
CN102612520A (zh) 2012-07-25
KR101363830B1 (ko) 2014-02-14
TW201127841A (en) 2011-08-16
MA33751B1 (fr) 2012-11-01
PL2501703T3 (pl) 2014-02-28
IL219370A0 (en) 2012-06-28
AR078863A1 (es) 2011-12-07
CA2796161C (en) 2015-03-17
EA020848B1 (ru) 2015-02-27
PH12012500969A1 (en) 2013-01-07
EP2501703B1 (en) 2013-09-18
RS53018B (sr) 2014-04-30
IL219370A (en) 2015-01-29
DOP2012000135A (es) 2012-08-15
JP2013510859A (ja) 2013-03-28
EP2501703A1 (en) 2012-09-26
NZ600006A (en) 2014-05-30
AU2010319581C1 (en) 2014-05-15
AU2010319581B2 (en) 2013-12-19
MY160665A (en) 2017-03-15
CN102612520B (zh) 2015-04-08
DK2501703T3 (da) 2013-10-14
US8232289B2 (en) 2012-07-31
PE20121430A1 (es) 2012-10-26
HN2012001011A (es) 2015-08-31
ECSP12011902A (es) 2012-07-31
US20110118251A1 (en) 2011-05-19
TWI465453B (zh) 2014-12-21
MX2012005691A (es) 2012-06-13
CR20130087A (es) 2013-04-17
ES2435814T3 (es) 2013-12-23
KR20130026523A (ko) 2013-03-13
AU2010319581A1 (en) 2012-06-07
HK1169988A1 (en) 2013-02-15
CA2796161A1 (en) 2011-05-19
UA107943C2 (xx) 2015-03-10
PT2501703E (pt) 2013-11-26
EA201290352A1 (ru) 2012-10-30
HRP20130967T1 (hr) 2013-11-22
ME01537B (me) 2014-04-20
ZA201202967B (en) 2013-09-25
CO6541545A2 (es) 2012-10-16
SI2501703T1 (sl) 2013-11-29

Similar Documents

Publication Publication Date Title
JO2887B1 (en) Spiro-pyridine compounds as ORL-1 receptor antagonists
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
GB201017345D0 (en) Receptor antagonists
TN2011000673A1 (en) Bace inhibitors
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
GEP201706745B (en) Forms of rifaximin and usage thereof
AU2012209332A8 (en) Methods and compositions for preparing noribogaine from voacangine
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
PL2531505T3 (pl) Sposób wytwarzania kompleksów 3,7-diaza-bicyklo[3.3.1]nonanu z metalami
IN2012DN03404A (enExample)
PH12013500991A1 (en) 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS
MX341132B (es) Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.
MX2013005623A (es) Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
MX2011008458A (es) Metodos para preparar agonistas y antagonistas del receptor s1p.
WO2011137331A3 (en) 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
WO2010008734A3 (en) Methods of Preparing Imidazole-Based Bicyclic Compounds
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
PL2531504T3 (pl) Sposób wytwarzania roztworów kompleksów metali z 3,7-diazabicyklo[3.3.1]nonanem
UA50733U (ru) Применение антагониста рецепторов интерлейкина-1 (АРИЛ-1) в качестве средства антиалкогольного действия
UA54879U (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиоксидантного действия
UA51902U (ru) Применение антагониста рецепторов интерлейкина-1 (арил-1) в качестве способа фригопротекторного действия
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия